

Synthesis and Biological Activity of Phospholipase C-Resistant Analogues of Phosphatidylinositol 4,5-bisphosphate

Honglu Zhang,[†] Yong Xu,[†] Zheng Zhang,[‡] Emily R. Liman,[‡] and Glenn D. Prestwich^{*†}

Department of Medicinal Chemistry, University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, Utah 84108-1257, and Department of Biological Sciences and Program in Neuroscience, University of Southern California, 3641 Watt Way, Los Angeles, California 90089-2520

Received February 6, 2006; E-mail: gprestwich@pharm.utah.edu


The membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P₂) is an important regulator of cytoskeletal organization during a plethora of cellular functions, such as vesicle trafficking, endocytosis, phagocytosis, focal adhesion formation, and cell migration.¹ PtdIns(4,5)P₂ binds to and affects the function of many actin-binding and actin-remodeling proteins^{2–4} and is a cofactor in enzyme activation.⁵ In addition, PtdIns(4,5)P₂ regulates the activity of many ion channels and transporters.^{6,7} PtdIns(4,5)P₂ is also the source of three second messengers: Ins(1,4,5)P₃, diacylglycerol (DAG),^{8,9} and PtdIns(3,4,5)P₃.¹⁰ In many cases, it is the decrease in PtdIns(4,5)P₂, resulting from hydrolysis by phospholipase C (PLC) (Scheme 1), and not the increase in Ins(1,4,5)P₃ and DAG that constitutes the physiologically relevant signal.^{11,12} Hydrolysis of PtdIns(4,5)P₂ causes TRP channels to lose some activity.^{13–19} Moreover, addition of PtdIns(4,5)P₂ restores sensitivity of TRPM4 and TRPM5 to activation by Ca²⁺ and restores the sensitivity of TRPM8 and TRPV1 to thermal and chemical stimuli.^{15,16,18,19}

The availability of a metabolically stabilized analogue of PtdIns(4,5)P₂, that is, one that lacks the scissile P–O bond and thus could not be hydrolyzed by PLC activity, would have many applications in understanding the role of PtdIns(4,5)P₂ in cell physiology. α -Fluoroalkylphosphonates have emerged as important nonhydrolyzable mimics for phosphoesters in the synthesis of biologically active “unnatural products”.^{20–23} Herein we describe the first asymmetric total synthesis of isosteric and isoelectronic phosphonate analogues **1–5** of PtdIns(4,5)P₂ that cannot be hydrolyzed by PLC. The synthesis employs a Pd(0) coupling not previously exploited in phospholipid or phosphoinositide synthesis. Furthermore, we demonstrate that both saturated and unsaturated α -fluorophosphonate analogues can substitute for exogenous PtdIns(4,5)P₂ in restoring the sensitivity of the TRPM4 channel to Ca²⁺.


The synthetic sequence to the stabilized analogues **1–5** of PtdIns(4,5)P₂ is illustrated in Scheme 2. A variety of attempts to connect the intermediate **9**²⁴ with a fluoromethylenephosphonic acid synthon²¹ failed. Eventually, we turned to the Pd(0)-catalyzed coupling of an *H*-phosphite with a vinyl bromide in order to form the desired C–P linkage. Thus, coupling the protected inositol **9** with dibenzyl *N,N*-diisopropylphosphoramidite gave the phosphoramidite intermediate **10**, which was converted to *H*-phosphonate **11** in 76% isolated yield in two steps.²⁵ The 1-bromo-1-fluoroolefin **7** (~1:1 *E/Z*) was separately prepared via a Et₂Zn-promoted olefination reaction²⁶ of CBr₃F/PPh₃ with glyceraldehyde **6** in excellent yield.

Few examples exist of Pd(0)-catalyzed formation of P–CF bonds, and in our hands, only traces of coupled compound **12** with a majority of the P–O cleaved compound **9** were obtained under standard conditions using Et₃N or K₂CO₃ as base. It appeared that

Scheme 1. Phospholipase C Catalyzes Hydrolysis of PtdIns(4,5)P₂ to Two Second Messengers, Ins(1,4,5)P₃ and Diacylglycerol



Scheme 2. Synthesis of Phosphonates **1–5**^a



^a Conditions: (a) CBr₃F, PPh₃, Et₂Zn, THF, 76%; (b) (BnO)₂P(NPr₂-i)₂, *N,N*-diisopropylethylammonium **1H**-tetrazole, CH₂Cl₂, rt; (c) H₂O, 1*H*-tetrazole, rt, 1 h, CH₂Cl₂, 76% for two steps; (d) Pd(OAc)₂, dppf, propylene oxide, THF, 70 °C, 62%; (e) 60% aqueous TFA, THF, 0 °C, 1 h, 86%; (f) EDCI, DMAP, fatty acid, CH₂Cl₂, rt; (g) H₂, Pd/C, MeOH, 6 h, EtSH; (h) TMBR/TMSI (5:1), rt, 1.5 h; MeOH, 1 h.

the rate of decomposition was faster than the rate of coupling for the more hindered *H*-phosphonate **11**. To overcome this problem, we selected propylene oxide as a weak Lewis base and an effective scavenger of HBr.²⁷ Using this modification, treatment of the *H*-phosphonate **11** with Pd(OAc)₂/dppf/propylene oxide in THF at 70 °C led to the formation of α -fluorovinylphosphonate **12** in 62%

[†] University of Utah.

[‡] University of Southern California.




Figure 1. PtdIns(4,5)P₂ and analogues **2** and **4** restore TRPM4 currents following desensitization. (A) An excised inside-out patch from Chok1 cell expressing mouse TRPM4 (mTRPM4) shows activation and fast rundown of an inward current in the presence of 100 μ M Ca²⁺ and recovery by dioctanoyl-PtdIns(4,5)P₂ and analogues **2** and **4** (V_m = 80 mV). (B) Initial magnitudes of the mTRPM4 currents, currents after rundown, and currents after recovery in response to 10 μ M each of PtdIns(4,5)P₂, **2**, and **4** (averages, n = 8).

yield. Acetal **12** was selectively deprotected by treatment with 60% aqueous trifluoroacetic acid in tetrahydrofuran at 0 °C to give diol **13**. Next, acylation of **13** with either octanoic acid, palmitic acid, or oleic acid provided the fully protected phosphonates **14a**, **14b**, and **14c** in 80, 73, and 82% yields, respectively. Hydrogenolysis of **14a** and **14b** removed the benzyl groups, and then reaction with ethanethiol removed the MOM groups to give the α -fluoromethylenephosphonate analogues **1** and **2**.²⁸ The α -fluorovinylphosphonates **3**–**5**²⁸ were obtained by deprotection of benzyl and MOM groups simultaneously with TMSBr/TMSI (5:1).

Recently, the hydrolysis of the water-soluble dioctanoyl PtdIns(4,5)P₂ was found to be important in the desensitization of TRPM4 channel (activated by cytoplasmic Ca²⁺). Exogenous PtdIns(4,5)P₂ could restore the sensitivity of TRPM4 channels to Ca²⁺, demonstrating that PtdIns(4,5)P₂ was a general regulator for the gating of TRPM4 ion channels.¹⁵ The ability of the two dioctanoyl-PtdIns(4,5)P₂ analogues **2** and **4** to restore TRPM4 currents following rundown is shown in Figure 1. Both analogues restored TRPM4 sensitivity following desensitization, but the α -fluorovinylphosphonate **4** was more potent. Indeed, the unsaturated phosphonate **4** was even more effective than the hydrolyzable dioctanoyl-PtdIns(4,5)P₂ at restoring TRPM4 sensitivity. This provides further evidence that the regulation of TRPM4 by dioctanoyl-PtdIns(4,5)P₂ and the ability of dioctanoyl-PtdIns(4,5)P₂ to restore TRPM4 currents following rundown is not due to effects of products of PLC hydrolysis.¹⁵

To determine sensitivity of TRPM4 currents to **2** and **4**, we measured the effects of varying concentrations of both compounds on the recovery of TRPM4 currents in excised inside-out patches evoked in response to 100 μ M Ca²⁺ (Figure 2). Maximal recovery of TRPM4 currents was observed upon reaching 10 μ M for both **2** and **4**, and half-activation was observed at \sim 2 μ M for both compounds, which is similar to the concentration of PtdIns(4,5)P₂ that promoted half-activation of TRPM4 (6 μ M).¹⁵ The difference between the effectiveness of **2** and **4** in restoring TRPM4 currents (Figure 1) appears to result from differential abilities to promote activation of the TRPM4 channel. Taken together, these data suggest that the α -fluorovinylphosphonate **4** is a biologically active, long-lived mimic of PtdIns(4,5)P₂.

In conclusion, we developed an efficient synthesis of two nonhydrolyzable PtdIns(4,5)P₂ analogues, and we showed that α -fluorovinylphosphonate **4** optimally restored the sensitivity of




Figure 2. Dose-response for recovery of TRPM4 currents by **2** and **4**. After TRPM4 desensitization, recovery was assessed. Data were normalized to the response to 10 μ M of each analogue in the same patch. (A) Averaged data (n = 5) for recovery of TRPM4 currents by **2** (EC_{50} = 2.7 ± 0.6 μ M and n_H = 2.5 ± 1.2). (B) Averaged data (n = 6) for **4** (EC_{50} = 1.8 ± 0.1 μ M and n_H = 3.2 ± 0.5).

TRPM4 currents. These results suggest that metabolically stabilized analogues of PtdIns(4,5)P₂ will have a wide variety of applications in separating the role of the phosphoinositide per se from activities that result when Ins(1,4,5)P₃, DAG, Ca²⁺, or other downstream signals are generated from the hydrolysis of PtdIns(4,5)P₂ by PLC.

Acknowledgment. We thank the NIH (Grant NS 29632 to G.D.P. and DC 004564 to E.R.L.) for financial support of this work.

Supporting Information Available: Experimental details for synthesis and characterization of new compounds, and protocols for TRPM4 channel activity measurement. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- McLaughlin, S.; Murray, D. *Nature* **2005**, *438*, 605–611.
- Anderson, R. A.; Boronokov, I. V.; Doughman, S. D.; Kunz, J.; Loijens, J. C. *J. Biol. Chem.* **1999**, *274*, 9907–9910.
- Doughman, R. L.; Firestone, A. J.; Anderson, R. A. *J. Membr. Biol.* **2003**, *194*, 77–89.
- McLaughlin, S.; Wang, J.; Gambhir, A.; Murray, D. *Annu. Rev. Biophys. Biomol. Struct.* **2002**, *31*, 151–175.
- Sciorra, V. A.; Rudge, S. A.; Wang, J.; McLaughlin, S.; Engebrecht, J.; Morris, A. J. *J. Cell. Biol.* **2002**, *159*, 1039–1049.
- Hilgemann, D. W.; Feng, S.; Nasuhoglu, C. *Sci. STKE* **2001**, RE19.
- Suh, B. C.; Hille, B. *Curr. Opin. Neurobiol.* **2005**, *15*, 370–378.
- Berridge, M. J. *Nature* **1993**, *361*, 315–325.
- Berridge, M. J. *Annu. Rev. Biochem.* **1987**, *56*, 159–193.
- Cantley, L. C. *Science* **2002**, *296*, 1655–1657.
- Suh, B. C.; Hille, B. *Neuron* **2002**, *35*, 507–520.
- Zhang, H.; Craciun, L. C.; Mirshahi, T.; Rohacs, T.; Lopes, C. M.; Jin, T.; Logothetis, D. E. *Neuron* **2003**, *37*, 963–975.
- Chuang, H. H.; Prescott, E. D.; Kong, H.; Shields, S.; Jordt, S. E.; Basbaum, A. I.; Chao, M. V.; Julius, D. *Nature* **2001**, *411*, 957–962.
- Prescott, E. D.; Julius, D. *Science* **2003**, *300*, 1284–1288.
- Zhang, Z.; Okawa, H.; Wang, Y.; Liman, E. R. *J. Biol. Chem.* **2005**, *280*, 39185–39192.
- Liu, D.; Liman, E. R. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 15160–15165.
- Liu, B.; Zhang, C.; Qin, F. *J. Neurosci.* **2005**, *25*, 4835–4843.
- Liu, B.; Qin, F. *J. Neurosci.* **2005**, *25*, 1674–1681.
- Rohacs, T.; Lopes, C. M.; Michailidis, I.; Logothetis, D. E. *Nat. Neurosci.* **2005**, *8*, 626–634.
- Berkowitz, D. B.; Bose, M. J. *Fluorine Chem.* **2001**, *112*, 13–33.
- Xu, Y.; Prestwich, G. D. *J. Org. Chem.* **2003**, *68*, 5320–5330.
- Prestwich, G. D.; Xu, Y.; Qian, L.; Gajewiak, J.; Jiang, G. *Biochem. Soc. Trans.* **2005**, *33*, 1357–1361.
- Xu, Y.; Lee, S. A.; Kutateladze, T. G.; Sbrissa, D.; Shisheva, A.; Prestwich, G. D. *J. Am. Chem. Soc.* **2006**, *128*, 885–897.
- Kubiak, R. J.; Bruzik, K. S. *J. Org. Chem.* **2003**, *68*, 960–968.
- Chen, J.; Prestwich, G. D. *J. Org. Chem.* **1998**, *63*, 430–431.
- Lei, X.; Dutheil, G.; Pannecoucke, X.; Quirion, J. C. *Org. Lett.* **2004**, *6*, 2101–2104.
- Abbas, S.; Bertram, R. D.; Hayes, C. J. *Org. Lett.* **2001**, *3*, 3365–3367.
- Note on stereochemistry. Both compounds **1** and **2** are inseparable mixtures of diastereomers at the C–F stereocenter, and the chiral phosphorus atom is racemic. Similarly, compounds **3**, **4**, **5**, and **12**–**14** are inseparable *E/Z* mixtures.

JA060621D